Transcriptional Networks Implicated in Human Nonalcoholic Fatty Liver Disease

Overview

Journal Mol Genet Genomics

Specialty Genetics

Date 2015 Apr 9

PMID 25851235

Citations 12

Authors

Hua Ye

Wei Liu

Affiliations

Soon will be listed here.

Abstract

The transcriptome of nonalcoholic fatty liver disease (NAFLD) was investigated in several studies. However, the implications of transcriptional networks in progressive NAFLD are not clear and mechanisms inducing transition from nonalcoholic simple fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) are still elusive. The aims of this study were to (1) construct networks for progressive NAFLD, (2) identify hub genes and functional modules in these networks and (3) infer potential linkages among hub genes, transcription factors and microRNAs (miRNA) for NAFLD progression. A systems biology approach by combining differential expression analysis and weighted gene co-expression network analysis (WGCNA) was utilized to dissect transcriptional profiles in 19 normal, 10 NAFL and 16 NASH patients. Based on this framework, 3 modules related to chromosome organization, proteasomal ubiquitin-dependent protein degradation and immune response were identified in NASH network. Furthermore, 9 modules of co-expressed genes associated with NAFL/NASH transition were found. Further characterization of these modules defined 13 highly connected hub genes in NAFLD progression network. Interestingly, 11 significantly changed miRNAs were predicted to target 10 of the 13 hub genes. Characterization of modules and hub genes that may be regulated by miRNAs could facilitate the identification of candidate genes and pathways responsible for NAFL/NASH transition and lead to a better understanding of NAFLD pathogenesis. The identified modules and hub genes may point to potential targets for therapeutic interventions.

Citing Articles

Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression.

He J, Xiao C, Li C, Yang F, Du C Liver Res. 2025; 7(2):145-155.

PMID: 39958950 PMC: 11791902. DOI: 10.1016/j.livres.2023.06.001.

Altered splicing factor and alternative splicing events in a mouse model of diet- and polychlorinated biphenyl-induced liver disease.

Petri B, Piell K, Wahlang B, Head K, Rouchka E, Park J Environ Toxicol Pharmacol. 2023; 103:104260.

PMID: 37683712 PMC: 10591945. DOI: 10.1016/j.etap.2023.104260.

Identification of disease-related genes and construction of a gene co-expression database in non-alcoholic fatty liver disease.

Ye H, Sun M, Su M, Chen D, Liu H, Ma Y Front Genet. 2023; 14:1070605.

PMID: 37051599 PMC: 10083285. DOI: 10.3389/fgene.2023.1070605.

Alternative RNA Splicing in Fatty Liver Disease.

Wu P, Zhang M, Webster N Front Endocrinol (Lausanne). 2021; 12:613213.

PMID: 33716968 PMC: 7953061. DOI: 10.3389/fendo.2021.613213.

Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease.

Del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M J Clin Endocrinol Metab. 2019; 104(8):3389-3402.

PMID: 30901032 PMC: 6590982. DOI: 10.1210/jc.2019-00021.

References

Younossi Z, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born T . A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005; 42(3):665-74. DOI: 10.1002/hep.20838. View

Yang J, Li J, Shao P, Zhou H, Chen Y, Qu L . starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2010; 39(Database issue):D202-9. PMC: 3013664. DOI: 10.1093/nar/gkq1056. View

Sookoian S, Pirola C . The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis. 2012; 16(3):467-85. DOI: 10.1016/j.cld.2012.05.011. View

Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T . Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008; 294(5):G1281-7. DOI: 10.1152/ajpgi.00074.2008. View

Sookoian S, Pirola C . Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One. 2013; 8(3):e58895. PMC: 3596348. DOI: 10.1371/journal.pone.0058895. View

Latea L, Negrea S, Bolboaca S . Primary non-alcoholic fatty liver disease in hypertensive patients. Australas Med J. 2013; 6(6):325-30. PMC: 3702137. DOI: 10.4066/AMJ.2013.1648. View

Gawrieh S, Baye T, Carless M, Wallace J, Komorowski R, Kleiner D . Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010; 20(12):1698-709. PMC: 8375563. DOI: 10.1007/s11695-010-0171-6. View

Ray K . NASH: KLF6 activates PPARα signalling in hepatic steatosis. Nat Rev Gastroenterol Hepatol. 2013; 10(3):128. DOI: 10.1038/nrgastro.2013.26. View

Nieminen M, Henttinen T, Merinen M, Marttila-Ichihara F, Eriksson J, Jalkanen S . Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol. 2006; 8(2):156-62. DOI: 10.1038/ncb1355. View

10.

Hu Z, Hung J, Wang Y, Chang Y, Huang C, Huyck M . VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. Nucleic Acids Res. 2009; 37(Web Server issue):W115-21. PMC: 2703932. DOI: 10.1093/nar/gkp406. View

11.

Wang J, Maldonado M . The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol. 2006; 3(4):255-61. View

12.

Yang F, Zhang L, Wang F, Wang Y, Huo X, Yin Y . Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia. 2011; 13(7):590-600. PMC: 3132845. DOI: 10.1593/neo.11422. View

13.

Miller J, Oldham M, Geschwind D . A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci. 2008; 28(6):1410-20. PMC: 2902235. DOI: 10.1523/JNEUROSCI.4098-07.2008. View

14.

Ivliev A, t Hoen P, Sergeeva M . Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Cancer Res. 2010; 70(24):10060-70. DOI: 10.1158/0008-5472.CAN-10-2465. View

15.

Yoneda M, Endo H, Nozaki Y, Tomimoto A, Fujisawa T, Fujita K . Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci. 2007; 105(2):151-6. DOI: 10.1254/jphs.fm0070063. View

16.

Podrini C, Borghesan M, Greco A, Pazienza V, Mazzoccoli G, Vinciguerra M . Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). Curr Pharm Des. 2012; 19(15):2737-46. DOI: 10.2174/1381612811319150009. View

17.

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

18.

Pirola C, Fernandez Gianotti T, Castano G, Sookoian S . Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome. Hepatology. 2012; 57(6):2545-7. DOI: 10.1002/hep.26116. View

19.

Lake A, Novak P, Fisher C, Jackson J, Hardwick R, Billheimer D . Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011; 39(10):1954-60. PMC: 3186211. DOI: 10.1124/dmd.111.040592. View

20.

Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View